(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 August 2006 (24.08.2006)

PCT

(10) International Publication Number
WO 2006/088840 A1

(51) International Patent Classification:
C07D 401/14 (2006.01) *A61K 31/497* (2006.01)
C07D 413/14 (2006.01) *A61P 31/00* (2006.01)
C07D 417/14 (2006.01) *A61P 29/00* (2006.01)

(21) International Application Number:
PCT/US2006/005128

(22) International Filing Date:
14 February 2006 (14.02.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/653,332 16 February 2005 (16.02.2005) US

(71) Applicants *(for all designated States except US)*: **SCHERING CORPORATION** [US/US]; 2000 Galloping Hill Road, Kenilworth, New Jersey 07033-0530 (US). **PHARMACOPEIA DRUG DISCOVERY, INC.** [US/US]; 3000 Eastpark Boulevard, Cranbury, New Jersey 08512 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ANILKUMAR, Gopinadhan, N.** [IN/US]; 560 Darwin Boulevard, Edison, New Jersey 08820 (US). **ZENG, Qingbei** [CN/US]; 509 Cinder Road, Edison, New Jersey 08820 (US). **ROSENBLUM, Stuart, B.** [US/US]; 16 Steven Terrace, West Orange, New Jersey 07052 (US). **KOZLOWSKI, Joseph, A.** [US/US]; 1066 Stuart Road, Princeton, New Jersey 08540 (US). **MCGUINNESS, Brian, F.** [US/US]; 16 Adams Court, Plainsboro, New Jersey 08536 (US). **HOBBS, Douglas, W.** [US/US]; 1330 University Drive, Yardley, Pennsylvania 19067 (US).

(74) Agent: **BANERJEE, Krishna, G.**; SCHERING-PLOUGH CORPORATION, Patent Department, K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033-0530 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) **Title:** NOVEL HETEROCYCLIC SUBSTITUTED PYRIDINE OR PHENYL COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY



(1)

(57) **Abstract:** The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1 or a pharmaceutically acceptable salt, solvate or ester thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, zenograft rejection), infectious diseases (e.g , tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

WO 2006/088840 A1